Macroplastique治疗女性压力性尿失禁继发内括约肌缺陷的数据集

数据集获取（Figshare）

• 源站标题：Macroplastique for women with stress urinary incontinence secondary to intrinsic sphincter deficiency
• DOI：10.6084/m9.figshare.10295972.v1
• 发布日期：2019-11-13
• 文件数：6 个
• 文件总体积：317.78 KB
• 源站页面：https://scielo.figshare.com/articles/dataset/Macroplastique_for_women_with_stress_urinary_incontinence_secondary_to_intrinsic_sphincter_deficiency/10295972

命令行下载

curl -L -o "1677-5538-ibju-45-05-0989-gf01.jpg" "https://ndownloader.figshare.com/files/18709175"
curl -L -o "1677-5538-ibju-45-05-0989-gf02.jpg" "https://ndownloader.figshare.com/files/18709184"
curl -L -o "Table_1.xls" "https://ndownloader.figshare.com/files/18709193"
curl -L -o "Table_2.xls" "https://ndownloader.figshare.com/files/18709202"
curl -L -o "Table_3.xls" "https://ndownloader.figshare.com/files/18709211"
curl -L -o "Table_4.xls" "https://ndownloader.figshare.com/files/18709214"

文件清单

• 1677-5538-ibju-45-05-0989-gf01.jpg（129.50 KB）
• 1677-5538-ibju-45-05-0989-gf02.jpg（149.38 KB）
• Table_1.xls（9.73 KB）
• Table_2.xls（9.73 KB）
• Table_3.xls（9.73 KB）
• Table_4.xls（9.73 KB）

文件总体积 317.78 KB（源站 API 实测）。

数据加载示例（图像类）

from PIL import Image
import glob, os

files = (glob.glob(os.path.join(path, "**", "*.png"), recursive=True)
       + glob.glob(os.path.join(path, "**", "*.jpg"), recursive=True)
       + glob.glob(os.path.join(path, "**", "*.tif"), recursive=True))
print("图像文件数:", len(files))
img = Image.open(files[0]); print("尺寸/模式:", img.size, img.mode)

# torchvision Dataset 方式:
# from torchvision import datasets
# ds = datasets.ImageFolder(path)  # 要求 子目录=类别

目录组织与标注格式以源站说明和下载后实际文件为准。

数据说明

ABSTRACT Objective To evaluate the subjective and objective outcomes of Macroplastique® (MPQ) in women with stress urinary incontinence (SUI) secondary to intrinsic sphincter deficiency (ISD). Materials and Methods Following Institutional Review Board (IRB) approval, charts of non-neurogenic women with SUI secondary to ISD who underwent MPQ injection and had 6 months minimum follow-up were reviewed from a prospectively maintained database. Patients were divided into 3 groups: Naïve (Group I), Prior Anti-Incontinence Surgery (Group II), and combined Prior Bulking Agent and Anti-Incontinence Surgery (Group III). Data collected included SUI self-report, Urogenital Distress Inventory (UDI-6) Question 3, and VAS Quality of Life (QoL) Questionnaire scores at baseline and in follow-up. Three-dimensional ultrasound (3DUS) evaluated volume/configuration of MPQ. Success was defined after the last MPQ injection as a UDI-6 Question 3 score of 0 (dry) or 1, and no reoperation for SUI. Results From 2011-2017, 106 of 142 women met study criteria. At a median follow-up of 20 months (mean=26 months; range: 6-71), success rate was 41% for Group I, 40% for Group II, and 65% for Group III (p = 0.22). QoL scores were significantly improved over baseline in all groups. There was no significant difference in clinical outcome between the asymmetrical and symmetrical group on 3DUS. The completely dry rate was highest in Group III at 29%, compared to 4% for Group I and 15% for Group II (p = 0.05). Conclusion Macroplastique® improved subjective and objective outcome measures for SUI secondary to ISD as both a primary and secondary treatment option in women.

许可

CC BY 4.0

引用

学术使用请引用 DOI 10.6084/m9.figshare.10295972.v1（source: https://scielo.figshare.com/articles/dataset/Macroplastique_for_women_with_stress_urinary_incontinence_secondary_to_intrinsic_sphincter_deficiency/10295972）。